Top Markets
Coin of the day
Caladrius Biosciences, Inc. Caladrius Biosciences, Inc.

Caladrius Biosciences, Inc.

CLBS
Classificação em ações #33297
Caladrius Biosciences, Inc. operates as a clinical-stage biopharmaceutical... Caladrius Biosciences, Inc. operates as a clinical-stage biopharmaceutical company primarily engaged in the development and commercialization of cellular therapies. These therapies aim to either reverse various diseases or stimulate the regeneration of compromised tissue. The company's pipeline includes several key investigational therapies: HONEDRA, which has received the prestigious SAKIGAKE designation, is undergoing Phase II clinical trials as a potential treatment for critical limb ischemia; XOWNA is currently in Phase IIb trials targeting coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy, is being evaluated for chronic kidney disease in patients prior to requiring dialysis. Previously known as NeoStem, Inc., the firm adopted its current name, Caladrius Biosciences, Inc., in June 2015. Established in 1980, the company maintains its corporate headquarters in Basking Ridge, New Jersey.
Preço da ação
$0.4264
Última sincronização: 2022-09-14
Valor de mercado
$7.93M
Variação (1 dia)
-16.44%
Variação (1 ano)
0.00%
País
US
Negociar Caladrius Biosciences, Inc. (CLBS)

Categoria

Histórico de preços das ações de Caladrius Biosciences, Inc. (CLBS)
Preço de fecho mais alto: $0.50 em 2022-09-01

Preço de fecho mais baixo: $20.36 em 2015-06-01
Histórico de preços das ações da Caladrius Biosciences, Inc. de 2015 a 2026
Desempenho anual do preço das ações
Ano Desempenho
2022 -43.51%
2021 -42.36%
2020 -36.52%
2019 -44.38%
2018 26.20%
2017 2.72%
2016 -70.04%
2015 0.00%
Preço das ações de empresas similares ou concorrentes
Empresa Preço da ação Variação 1a% País
$505.24 28.63%
US
$846.09 29.41%
NL
$737.68 7.34%
CH
$1.07K -6.40%
KR
$254.55 12.96%
BE